CHMP recommends EU approval of Roche’s Tecentriq
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer.
Read More
